ALIM: Alimera Sciences Inc Company Short-Term Debt

Alimera Sciences (ALIM) has developed a unique sustained-release drug delivery technology for the retina, enabling a single procedure to replace frequent injections for several years. The business relies on a robust scientific foundation for creating microimplants to treat complex ocular pathologies. The asset's market value of 0.00, as illustrated on this chart, is supplemented by data regarding the operations of certified partner plants featuring modernized production lines for ophthalmological products.

Short-term debts accumulate all liabilities with a maturity horizon of up to one year, serving as a critical filter for solvency and strict compliance with bank covenants. By analyzing balance sheet short-term obligations, an investor can assess the extent to which the stable cash flow from the sale of Alimera Sciences (ALIM) patented implants covers current outflows, ensuring sustainable margins and capital protection during dividend payments.